Adaptive Phage Therapeutics To Prevent The Spread of Infection

One of the healthcare problems that has accelerated due to COVID has been bacterial infections that are increasingly resistant to antibiotics – local startup Adaptive Phage Therapeutics (APT) is working to address this crisis. APT is a clinical-stage company founded with help from TEDCO, a Maryland based venture capital leader to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. Adapting to the emergence of future antibiotic-resistant superbugs, APT’s precision targeted, genomically screened, and highly purified phage collection is dynamically expanding in response to the emergence of new bacterial strains.